Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


Synergistic Antifungal, Allelopatic and Anti-Proliferative Potential of Salvia officinalis L., and Thymus vulgaris L. Essential Oils.

Alexa E, Sumalan RM, Danciu C, Obistioiu D, Negrea M, Poiana MA, Rus C, Radulov I, Pop G, Dehelean C.

Molecules. 2018 Jan 16;23(1). pii: E185. doi: 10.3390/molecules23010185.


The public perception of the anaesthesiologist in Romania: a survey.

Onutu AH, Rus C, Acalovschi I.

Rom J Anaesth Intensive Care. 2017 Apr;24(1):21-28. doi: 10.21454/rjaic.7518.241.onu.


[A girl with self-harm treated with N-acetylcysteine (NAC)].

Rus CP.

Tijdschr Psychiatr. 2017;59(3):181-184. Dutch.


Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.

Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P; Italian Multiple Myeloma Network GIMEMA.

Haematologica. 2010 Jul;95(7):1144-9. doi: 10.3324/haematol.2009.017913. Epub 2010 Jan 6.


The treatment of the elderly multiple myeloma patients.

Cavallo F, Ambrosini MT, Rus C, Boccadoro M, Palumbo A.

Leuk Lymphoma. 2007 Mar;48(3):469-80. Review.


Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.

Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M; Italian Multiple Myeloma Network, Gimema.

J Thromb Haemost. 2006 Aug;4(8):1842-5. No abstract available.


Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.

Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT, Bringhen S, Gay F, Rus C, Cavallo F, Falco P, Massaia M, Musto P, Boccadoro M.

Clin Lymphoma Myeloma. 2006 May;6(6):475-7.


Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the programme?

Ojeda S, Anguita M, Delgado M, Atienza F, Rus C, Granados AL, Ridocci F, Vallés F, Velasco JA.

Eur J Heart Fail. 2005 Aug;7(5):921-6.


Lupus anticoagulant: performance of a new, fully automated commercial screening and confirmation assay.

Montaruli B, Vaccarino A, Foli C, Rus C, Agnes C, Saitta M, Bazzan M.

Clin Chem. 2005 Jun;51(6):1031-3. No abstract available.


Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis.

Rus C, Bazzan M, Palumbo A, Bringhen S, Boccadoro M.

J Thromb Haemost. 2004 Nov;2(11):2063-5. No abstract available.


Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.

Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M.

Blood. 2004 Nov 15;104(10):3052-7. Epub 2004 Jul 20.


[Short-term results with the ross procedure. Does the etiology of aortic valvulopathy affect the outcome?].

Rus C, Mesa D, Concha M, Casares J, Suárez De Lezo J, Delgado M, Franco M, Romo E, Ruiz M, Vallés F.

Rev Esp Cardiol. 2004 Jun;57(6):531-7. Spanish.


Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2)).

Palumbo A, Bringhen S, Bertola A, Cavallo F, Falco P, Massaia M, Bruno B, Rus C, Barbui A, Caravita T, Musto P, Pescosta N, Rossini F, Vignetti M, Boccadoro M.

Leukemia. 2004 Jan;18(1):133-8.


[Prevalence of patent foramen ovale in young patients with cerebral ischemic accident of unknown origin].

Mesa D, Franco M, Suárez de Lezo J, Muñoz J, Rus C, Delgado M, Ruiz M, Pan M, Romo E, Vallés F, Viñals M, Bescansa E.

Rev Esp Cardiol. 2003 Jul;56(7):662-8. Spanish.


[Late recovery of coronary flow reserve in patients successfully treated with a percutaneous procedure].

Pan M, Suárez de Lezo J, Medina A, Romero M, Segura J, Pavlovic D, Hernández E, Muñoz J, Rodríguez M, Rus C, Delgado M, Ojeda S.

Rev Esp Cardiol. 2003 May;56(5):459-64. Spanish.


Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.

Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, Rus C, Bertola A, Giaccone L, Omedè P, Musto P.

Haematologica. 2002 Aug;87(8):846-50.


Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.

Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M.

Haematologica. 2001 Apr;86(4):399-403.


Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients.

Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, Omedè P, Tarella C, Pileri A, Boccadoro M.

Blood. 1999 Aug 15;94(4):1248-53.


Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history.

Bertini M, Rus C, Freilone R, Botto B, Calvi R, Novero D, Orsucci L, Vitolo U, Palestro G, Resegotti L.

Haematologica. 1998 Apr;83(4):312-6.

Supplemental Content

Support Center